Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer

Seung Hyeun Lee, Ji Sung Lee, Eun Joo Lee, Kyung Hoon Min, Gyu Young Hur, Seung Heon Lee, Sung Yong Lee, Je Hyeong Kim, Sang Yeub Lee, Chol Shin, Jae Jeong Shim, Kyung Ho Kang, Kwang Ho In

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)


Objectives: Reactive oxygen species modulator 1 (Romo1) is a novel protein that localizes in the mitochondrial membrane and induces mitochondrial reactive oxygen species (ROS) generation. Romo1 is increased in most cancer cell lines and is related with resistance to chemotherapy in vitro. However, data on its expression in patients with malignancy is very limited. We evaluated the usefulness of serum Romo1 as a potential diagnostic biomarker in non-small cell lung cancer (NSCLC). Materials and methods: We initially assessed the expression of Romo1 using Western blotting and enzyme-linked immunosorbent assay in paired lung tissue and serum specimen from NSCLC patients who underwent surgical resection. Then we evaluated and compared serum Romo1 level in a healthy population (n= 55), patients with benign lung diseases (n= 63) and NSCLC patients (n= 58). We explored the correlation between Romo1 expression and clinical parameters and assessed diagnostic performance of serum Romo1 for NSCLC using receiver operating characteristic (ROC) curve analysis. Results: Romo1 expression in lung cancer tissues was significantly increased compared with non-tumorous tissues (p< 0.001). Romo1 expression in cancer tissues positively correlated with that in serum (r= 0.68, p= 0.009). Serum Romo1 level in NSCLC patients significantly increased compared with that of healthy population or patients with benign lung diseases (both p< 0.001). ROC curve analysis using an optimal cutoff value of 329.7. pg/mL revealed sensitivity and specificity for the diagnosis of NSCLC of 81.9% and 89.8%, respectively, with an area under the curve of 0.847 (95% confidence interval: 0.789-0.892, p< 0.001). Serum Romo1 level was not related with age, gender, smoking status, tumor differentiation, histological type or stage. Conclusions: Serum Romo1 discriminated NSCLC patients from the population without cancer with considerable sensitivity and specificity. Serum Romo1 could be a potential diagnostic biomarker for NSCLC.

Original languageEnglish
Pages (from-to)175-181
Number of pages7
JournalLung Cancer
Issue number2
Publication statusPublished - 2014 Aug

Bibliographical note

Funding Information:
This study was supported by grant of the Korea National Enterprise for Clinical Trials (KoNECT) Regional Clinical Trial Center Project, Ministry of Health & Welfare, Republic of Korea ( A070001 ).


  • Biomarker
  • Diagnosis
  • Non-small cell lung cancer
  • Oxidative stress
  • Reactive oxygen species
  • Serum

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


Dive into the research topics of 'Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this